Every 10-Q that Guardant Health, Inc. (GH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GH filings page.
Guardant Health, Inc. reported rapid top-line growth but continued losses for the three and six months ended June 30, 2026. Q2 revenue was $334,978 (thousands) versus $232,088 (thousands) a year earlier, driven by oncology revenue of $219,105 (thousands) (prior-year $158,685) and screening revenue of $52,866 (thousands) (prior-year $14,814). Net loss for Q2 was $120,142 (thousands), or $0.90 per share, compared with $99,899 (thousands); for the first half, net loss was $232,217 (thousands) on revenue of $636,643 (thousands) versus $435,559 (thousands).
As of June 30, 2026, cash and cash equivalents were $1,053,469 (thousands) and restricted cash was $114,270 (thousands), with no short-term marketable securities, while long-term convertible senior notes had a net carrying amount of $1,502,943 (thousands). Stockholders’ deficit widened to $222,867 (thousands), reflecting an accumulated deficit of $3,226,729 (thousands) and 133.6 million common shares outstanding at quarter-end.
The company describes a broad precision oncology and screening portfolio, including FDA-approved Guardant360 CDx tests and the Shield blood test for colorectal cancer screening, which has FDA approval, Medicare coverage and guideline inclusion. Legal contingencies include a patent verdict in favor of TwinStrand Biosciences and the University of Washington, for which Guardant has recorded an $83.4 million liability and disclosed an estimated possible loss range through June 30, 2026 of zero to $250 million.
Guardant Health, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $301.7 million from $203.5 million a year earlier, driven by oncology, biopharma and data, and a sharp increase in screening revenue.
The company posted a net loss of $112.1 million, compared with a $95.2 million loss, with higher sales and marketing and ongoing R&D spending. Cash, cash equivalents and restricted cash totaled $1.10 billion, while convertible senior notes had a net carrying amount of $1.50 billion, leaving Guardant in a stockholders’ deficit of $181.1 million.
Guardant continues to expand its precision oncology and colorectal screening portfolio, including FDA‑approved Shield and Guardant360 tests, while managing significant legal matters. A prior $83.4 million patent verdict against the company remains under challenge, and Guardant has a $287.0 million false‑advertising judgment in its favor in separate litigation.
Guardant Health (GH) filed its Q3 2025 10-Q, reporting higher revenue and a narrower loss. Revenue rose to $265,196,000 from $191,476,000 a year ago, while net loss improved to $92,725,000 from $107,754,000. Loss per share was $0.74 versus $0.88.
Growth was broad-based: Oncology revenue was $184,402,000, Biopharma and data $54,731,000, Screening $24,112,000, and Licensing and other $1,951,000. For the nine months, revenue totaled $700,755,000, with a net loss of $287,783,000.
Cash and cash equivalents were $580,013,000, with restricted cash of $109,502,000; total assets were $1,276,786,000. Operating cash outflow for the nine months was $158,387,000. The company exchanged $659,300,000 of 2027 notes for $600,000,000 of 1.25% notes due 2031, recording a $13,672,000 gain and leaving $490,700,000 of 2027 notes outstanding. Treasury stock repurchases were $45,010,000 for 976,351 shares. As of October 24, 2025, 126,041,089 common shares were outstanding.